Presbyopia lens launch

Article

Oculentis will present its presbyopia correcting LENTIS Mplus IOL at DOC 2009 in Nuremberg to an expert audience. It claims the lens features a completely new approach in multi-focal lens technology.

Oculentis will present its presbyopia correcting LENTIS Mplus IOL at DOC 2009 in Nuremberg to an expert audience. It claims the lens features a completely new approach in multi-focal lens technology.

The main feature of this multifocal lens is its aspheric multi-curve design comprising a segment shaped near-vision section characterized by seamless transitions between the near and far vision zones.

Various benefits for the patient are said to result from this innovative design. In particular, reflections and image jumps as usually in twilight light conditions or in central headlight glare conditions will no longer occur. Furthermore the MIOL is pupil independent, offers true +3 D addition and ensures a minimal loss of light.

A multi-center study conducted under the leadership of Professor G. U. Auffarth of Heidelberg University Eye Clinic analyzed the results obtained by the implantation of the lens in 114 eyes of 69 patients (mean age: 68 ± 12 years). Oculentis says this confirmed the functional outcomes achieved with the MIOL as well as a very high degree of patient satisfaction. No complications were seen in both, unilateral and bilateral implantation. Mean IOL power came to 21.00 ± 2.01 D Three months after surgery, a best corrected distance visual acuity of 0.01 ± 0.14 logMAR was measured. Uncorrected near visual acuity came to 0.08 ± 0.17 logMAR.

Using the computer-controlled SML technology, each LENTIS Mplus IOL will be customized to the special needs of the individual patient and is made from the well-proved HydroSmart material.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.